caa a22 4500 465761917 CHVBK 20180323111901.0 cr unu---uuuuu 170327e19901201xx s 000 0 eng 10.1007/BF02987104 doi (NATIONALLICENCE)springer-10.1007/BF02987104 Simplified long term large scale production of highly active human lak cells for therapy [Elektronische Daten] [P. WersÄll, G. Masucci, P. Pihlstedt, H. Wigzel, H. Mellstedt] Cells obtained by leukapheresis and separated without or with a Ficoll-Isopaque (FIP) gradient were cultured for 4 or 20 days to determine whether a more effective LAK cell population could be obtained compared to LAK cells generated by the commonly used method (FIP separated cells cultured for 4 days). After leukapheresis the cells were separated on a FIP gradient (FIP cells) or only washed to minimize platelet contamination (non-FIP cells). In some experiments, the cells were also pretreated with phenylalanine-methylester (PheOMe) to reduce monocytes. After culturing for 20 days in the presence of IL-2 (100 BRMP U ml-1) a significantly higher total number of CD3+ and CD56+ cells was noted in the non-FIP fraction compared to the FIP fraction. The total lytic activity of non-FIP cells (LU/tot. no. of cells) against Daudi targets after 4 days of culture was 11,820 ± 624 versus 4770 ± 550 of FIP cells (P < 0.05). After 20 days of culture the non-FIP fraction exhibited a higher cytotoxic activity than the FIP cell fraction, 76,291 ± 20,053 compared to 7169 ± 1148 LU (P < 0.05). Pretreatment of the cells with PheOMe induced a significantly more effective cytotoxic population when cultured for 4 days. However, at 20 days PheOMe did not enhance the LAK cell activity. Large scale production of LAK cells can be accomplished without FIP separation with an increased cell yield and cytotoxicity compared to FIP separated cells both in short and long time cultures. Humana Press Inc., 1990 LAK cells nationallicence IL-2 nationallicence Long term culture nationallicence WersÄll P. Department of Oncology (Radiumhemmet), Immunologic Research Laboratory, S-104 01, Stockholm, Sweden aut Masucci G. Department of Oncology (Radiumhemmet), Immunologic Research Laboratory, S-104 01, Stockholm, Sweden aut Pihlstedt P. Department of Transfusion Medicine, Karolinska Hospital, Stockholm, Sweden aut Wigzel H. Department of Immunology, Karolinska Institute, Stockholm, Sweden aut Mellstedt H. Department of Oncology (Radiumhemmet), Immunologic Research Laboratory, S-104 01, Stockholm, Sweden aut Medical Oncology and Tumor Pharmacotherapy Humana Press 7/4(1990-12-01), 257-263 0736-0118 7:4<257 1990 7 12032 https://doi.org/10.1007/BF02987104 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02987104 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- WersÄll P. Department of Oncology (Radiumhemmet), Immunologic Research Laboratory, S-104 01, Stockholm, Sweden aut NATIONALLICENCE 700 1- Masucci G. Department of Oncology (Radiumhemmet), Immunologic Research Laboratory, S-104 01, Stockholm, Sweden aut NATIONALLICENCE 700 1- Pihlstedt P. Department of Transfusion Medicine, Karolinska Hospital, Stockholm, Sweden aut NATIONALLICENCE 700 1- Wigzel H. Department of Immunology, Karolinska Institute, Stockholm, Sweden aut NATIONALLICENCE 700 1- Mellstedt H. Department of Oncology (Radiumhemmet), Immunologic Research Laboratory, S-104 01, Stockholm, Sweden aut NATIONALLICENCE 773 0- Medical Oncology and Tumor Pharmacotherapy Humana Press 7/4(1990-12-01), 257-263 0736-0118 7:4<257 1990 7 12032 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer